F
Fabien Zoulim
Researcher at French Institute of Health and Medical Research
Publications - 716
Citations - 40988
Fabien Zoulim is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Hepatitis B virus & Hepatitis B. The author has an hindex of 96, co-authored 641 publications receiving 35807 citations. Previous affiliations of Fabien Zoulim include Hotel Dieu Hospital & University of Orléans.
Papers
More filters
Journal ArticleDOI
Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡
Markus Cornberg,Anna S.F. Lok,Norah A. Terrault,Fabien Zoulim,Thomas Berg,Maurizia Rossana Brunetto,Stephanie Buchholz,Maria Buti,Henry Lik-Yuen Chan,Kyong-Mi Chang,Maura Dandri,Geoffrey Dusheiko,Jordan J. Feld,Carlo Ferrari,Marc G. Ghany,Harry L.A. Janssen,Patrick T F Kennedy,Pietro Lampertico,Jake Liang,Stephen Locarnini,Mala K. Maini,Poonam Mishra,George V. Papatheodoridis,Jörg Petersen,Silke Schlottmann,Su Wang,Heiner Wedemeyer +26 more
TL;DR: For HBV 'functional cure', sustained HBsAg loss with undetectable HBV DNA after completion of treatment is the primary goal and sustained undetECTable HBv DNA without HBs Ag loss after stopping treatment an intermediate goal.
Journal ArticleDOI
Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure.
Stéphanie Villet,Stéphanie Villet,Christian Pichoud,Christian Pichoud,Gaëtan Billioud,Gaëtan Billioud,Luc Barraud,Sandra Durantel,Christian Trepo,Christian Trepo,Fabien Zoulim,Fabien Zoulim +11 more
TL;DR: The observations suggest that a single amino acid change at position rt181 may induce cross-resistance to lamivudine and adefovir, and emphasize the clinical relevance of genotypic and phenotypic analysis in the management of antiviral drug resistance.
Journal ArticleDOI
Hepatitis B cure: From discovery to regulatory approval.
TL;DR: Development of standardized assays for novel biomarkers toward better defining hepatitis B virus cure should occur in parallel with development of novel antiviral and immune modulatory therapies such that approval of new treatments can be linked to the approval ofnew diagnostic assays used to measure efficacy or to predict response.
Journal ArticleDOI
Line Probe Assay for Monitoring Drug Resistance in Hepatitis B Virus-Infected Patients during Antiviral Therapy
Lieven Stuyver,Caroline Van Geyt,Sija De Gendt,Georges Van Reybroeck,Fabien Zoulim,Geert Leroux-Roels,Rudi Rossau +6 more
TL;DR: This line probe assay detected the complex quasispecies nature of HBV and provided some insight into the dynamics of resistance mutations.
Journal ArticleDOI
Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians
Pauline Arends,Milan J. Sonneveld,Roeland Zoutendijk,Ivana Carey,Ashley Brown,Massimo Fasano,David Mutimer,Katja Deterding,Jurriën G.P. Reijnders,Y.H. Oo,Jörg Petersen,Florian van Bömmel,Robert J. de Knegt,Teresa Santantonio,Thomas Berg,Tania M. Welzel,Heiner Wedemeyer,Maria Buti,Pierre Pradat,Fabien Zoulim,Bettina E. Hansen,Harry L.A. Janssen,Harry L.A. Janssen +22 more
TL;DR: Cumulative incidence of HCC is low in patients treated with ETV, but ETV does not eliminate the risk of H CC, and predictive performances after 1 year were comparable to those at baseline.